The current study investigated the mechanisms underlying the developmental decline in cross-species intersensory matching first reported by Lewkowicz and Ghazanfar [Lewkowicz, D.J., & Ghazanfar, A.A., (2006). The decline of cross-species intersensory perception in human infants. Proc. Natl. Acad. Sci. U. S. A. 103(17), 6771-6774] and whether the decline persists into later development. Experiment 1 investigated whether infants can match monkey vocalizations to asynchronously presented faces and found that neither 4-6 nor 8-10 month-old infants did. Experiment 1 also assessed whether a visual processing deficit may account for the developmental decline in cross-species matching and indicated that it does not because both age groups discriminated silent monkey calls. Experiment 2 investigated whether an auditory processing deficit may account for the decline and indicated that it does not because 8-10 month-old infants discriminated the acoustic versions of the calls. Finally, Experiment 3 asked whether the developmental decline persists into later development by testing cross-species intersensory matching in 12- and 18-month-old infants and showed that it does because neither age group made intersensory matches. Together, these results bolster prior evidence of a decline in cross-species intersensory integration in early human development and shed new light on the mechanisms underlying it.

In a double-blind, randomized and crossover manner, 25 resistance-trained participants ingested a placebo (PLA) beverage containing 12 g of dextrose and a beverage (RTD) containing caffeine (200 mg), β-alanine (2.1 g), arginine nitrate (1.3 g), niacin (65 mg), folic acid (325 mcg), and Vitamin B12 (45 mcg) for 7-days, separated by a 7–10-day. On day 1 and 6, participants donated a fasting blood sample and completed a side-effects questionnaire (SEQ), hemodynamic challenge test, 1-RM and muscular endurance tests (3 × 10 repetitions at 70% of 1-RM with the last set to failure on the bench press (BP) and leg press (LP)) followed by ingesting the assigned beverage. After 15 min, participants repeated the hemodynamic test, 1-RM tests, and performed a repetition to fatigue (RtF) test at 70% of 1-RM, followed by completing the SEQ. On day 2 and 7, participants donated a fasting blood sample, completed the SEQ, ingested the assigned beverage, rested 30 min, and performed a 4 km cycling time-trial (TT). Data were analyzed by univariate, multivariate, and repeated measures general linear models (GLM), adjusted for gender and relative caffeine intake. Data are presented as mean change (95% CI). An overall multivariate time × treatment interaction was observed on strength performance variables (p = 0.01). Acute RTD ingestion better maintained LP 1-RM (PLA: −0.285 (−0.49, −0.08); RTD: 0.23 (−0.50, 0.18) kg/kgFFM, p = 0.30); increased LP RtF (PLA: −2.60 (−6.8, 1.6); RTD: 4.00 (−0.2, 8.2) repetitions, p = 0.031); increased BP lifting volume (PLA: 0.001 (−0.13, 0.16); RTD: 0.03 (0.02, 0.04) kg/kgFFM, p = 0.007); and, increased total lifting volume (PLA: −13.12 (−36.9, 10.5); RTD: 21.06 (−2.7, 44.8) kg/kgFFM, p = 0.046). Short-term RTD ingestion maintained baseline LP 1-RM (PLA: −0.412 (−0.08, −0.07); RTD: 0.16 (−0.50, 0.18) kg/kgFFM, p = 0.30); LP RtF (PLA: 0.12 (−3.0, 3.2); RTD: 3.6 (0.5, 6.7) repetitions, p = 0.116); and, LP lifting volume (PLA: 3.64 (−8.8, 16.1); RTD: 16.25 (3.8, 28.7) kg/kgFFM, p = 0.157) to a greater degree than PLA. No significant differences were observed between treatments in cycling TT performance, hemodynamic assessment, fasting blood panels, or self-reported side effects.

This study examined the effects of acute paraxanthine (PXN) ingestion on markers of cognition, executive function, and psychomotor vigilance. In a randomized, double blind, placebo-controlled, crossover, and counterbalanced manner, 13 healthy male and female participants were randomly assigned to consume a placebo (PLA) or 200 mg of PXN (ENFINITY™, Ingenious Ingredients, L.P.). Participants completed stimulant sensitivity and side effect questionnaires and then performed the Berg Wisconsin Card Sorting Test (BCST), the Go/No-Go test (GNG), the Sternberg task test (STT), and the psychomotor vigilance task test (PVTT). Participants then ingested one capsule of PLA or PXN treatment. Participants completed side effect and cognitive function tests after 1, 2, 3, 4, 5, and 6 h after ingestion of the supplement. After 7 days, participants repeated the experiment while consuming the alternative treatment. Data were analyzed by general linear model (GLM) univariate analyses with repeated measures using body mass as a covariate, and by assessing mean and percent changes from baseline with 95% confidence intervals (CIs) expressed as means (LL, UL). PXN decreased BCST errors (PXN −4.7 [−0.2, −9.20], p = 0.04; PXN −17.5% [−36.1, 1.0], p = 0.06) and perseverative errors (PXN −2.2 [−4.2, −0.2], p = 0.03; PXN −32.8% [−64.4, 1.2], p = 0.04) at hour 6. GNG analysis revealed some evidence that PXN ingestion better maintained mean accuracy over time and Condition R Round 2 response time (e.g., PXN −25.1 [−52.2, 1.9] ms, p = 0.07 faster than PLA at 1 h), suggesting better sustained attention. PXN ingestion improved STT two-letter length absent and present reaction times over time as well as improving six-letter length absent reaction time after 2 h (PXN −86.5 ms [−165, −7.2], p = 0.03; PXN −9.0% [−18.1, 0.2], p = 0.05), suggesting that PXN enhanced the ability to store and retrieve random information of increasing complexity from short-term memory. A moderate treatment x time effect size (ηp2 = 0.08) was observed in PVTT, where PXN sustained vigilance during Trial 2 after 2 h (PXN 840 ms [103, 1576], p = 0.03) and 4 h (PXN 1466 ms [579, 2353], p = 0.002) compared to PL. As testing progressed, the response time improved during the 20 trials and over the course of the 6 h experiment in the PXN treatment, whereas it significantly increased in the PL group. The results suggest that acute PXN ingestion (200 mg) may affect some measures of short-term memory, reasoning, and response time to cognitive challenges and help sustain attention.

In a double-blind, crossover, randomized and placebo-controlled trial; 28 men and women ingested a placebo (PLA), 3 g of creatine nitrate (CNL), and 6 g of creatine nitrate (CNH) for 6 days. Participants repeated the experiment with the alternate supplements after a 7-day washout. Hemodynamic responses to a postural challenge, fasting blood samples, and bench press, leg press, and cycling time trial performance and recovery were assessed. Data were analyzed by univariate, multivariate, and repeated measures general linear models (GLM). No significant differences were found among treatments for hemodynamic responses, clinical blood markers or self-reported side effects. After 5 days of supplementation, one repetition maximum (1RM) bench press improved significantly for CNH (mean change, 95% CI; 6.1 [3.5, 8.7] kg) but not PLA (0.7 [−1.6, 3.0] kg or CNL (2.0 [−0.9, 4.9] kg, CNH, p = 0.01). CNH participants also tended to experience an attenuated loss in 1RM strength during the recovery performance tests following supplementation on day 5 (PLA: −9.3 [−13.5, −5.0], CNL: −9.3 [−13.5, −5.1], CNH: −3.9 [−6.6, −1.2] kg, p = 0.07). After 5 days, pre-supplementation 1RM leg press values increased significantly, only with CNH (24.7 [8.8, 40.6] kg, but not PLA (13.9 [−15.7, 43.5] or CNL (14.6 [−0.5, 29.7]). Further, post-supplementation 1RM leg press recovery did not decrease significantly for CNH (−13.3 [−31.9, 5.3], but did for PLA (−30.5 [−53.4, −7.7] and CNL (−29.0 [−49.5, −8.4]). CNL treatment promoted an increase in bench press repetitions at 70% of 1RM during recovery on day 5 (PLA: 0.4 [−0.8, 1.6], CNL: 0.9 [0.35, 1.5], CNH: 0.5 [−0.2, 0.3], p = 0.56), greater leg press endurance prior to supplementation on day 5 (PLA: −0.2 [−1.6, 1.2], CNL: 0.9 [0.2, 1.6], CNH: 0.2 [−0.5, 0.9], p = 0.25) and greater leg press endurance during recovery on day 5 (PLA: −0.03 [−1.2, 1.1], CNL: 1.1 [0.3, 1.9], CNH: 0.4 [−0.4, 1.2], p = 0.23). Cycling time trial performance (4 km) was not affected. Results indicate that creatine nitrate supplementation, up to a 6 g dose, for 6 days, appears to be safe and provide some ergogenic benefit.

We previously reported that consuming a food bar (FB)containing whey protein and the plant fiber isomalto‐oligosaccharides [IMO] hada lower glycemic but similar insulinemic response as a high glycemic indexcarbohydrate. Therefore, we hypothesized that ingestion of this FB prior to, during, and following intense exercise would better maintain glucosehomeostasis and exercise capacity during exercise as well as hasten recovery incomparison to a carbohydrate matched placebo (PLA). Twelve resistance‐trainedmales participated in an open label, randomized, counterbalanced, cross‐overtrial with a 7‐d washout period. Participants consumed a carbohydrate matcheddextrose PLA or a FB containing 20 g of whey, 25 g of IMO, and 7 g of fat 30‐min prior to, mid‐way, and following intense exercise. Participantsperformed 11 resistance‐exercises (3 sets of 10 repetitions at 70% of onerepetition maximum) followed by performing agility and sprint conditioningdrills for time. Participants donated blood samples, performed isokineticstrength tests, and rated perceptions of muscle soreness and hypoglycemia priorto and following exercise and after 48 hours of recovery. Data were analyzed bygeneral linear model repeated measures and are reported as mean change frombaseline with 95% confidence intervals. Results revealed that blood glucose wassignificantly higher 30‐min post‐ingestion with PLA (PLA 3.1 [2.0, 4.3], FB 0.8[0.2, 1.5] mmol/L, p=0.001) while post‐exercise ratio of insulin to glucose wasgreater with FB (PLA 0.04 [0.00, 0.08], FB 0.11 [0.07, 0.15], p=0.013, η2=0.25). Total lifting volume was maintained toa greater degree from Set 1 to Set 3 with FB than PLA (PLA −198.26 [−320.1, −76.4], FB −81.7 [−203.6, 40.1] kg, p=0.175, η2=0.08). Ratings of muscle soreness of thedistal vastus medialis to a standard amount of pressure were lower with FB (PLA1.88 [0.60, 3.17]; FB 0.29 [−0.99, 1.57] cm, p=0.083, η2=0.13). However, no significant differences were observed between treatments in sprintperformance, isokinetic strength, markers of catabolism, stress and sexhormones, or inflammatory markers. Results indicate that ingestion ofthis FB can positively affect glucose homeostasis, sustain exerciseperformance, and lessen perceptions of muscle soreness after intense training. Support or Funding Information This study was supported internally by Dr. Richard B. Kreider and the Exercise and Sport Nutrition Laboratory at Texas A&M University as part of a student dissertation. Dr. Conrad Earnest served as a Director of Clinical Sciences for Nutrabolt. Dr. Kreider served as a university approved scientific advisor for Nutrabolt. Dr. Peter Murano serves as Texas A&M University approved quality assurance supervisor. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.